AstraZeneca’s experimental drug disappoints in breast cancer survival trial

AstraZeneca said its experimental precision drug, developed with Japan’s Daiichi Sankyo, significantly improved overall survival for patients with a type of breast cancer in a late-stage trial. However, overall survival did not reach statistical significance compared with chemotherapy.

Teile diesen Beitrag:

BELIEBTE BEITRÄGE
FOLGEN SIE UNS
Like uns auf Facebook
Folge uns auf Twitter
Abonniere unseren Kanal
Tick Tack
LIVEÜBERTRAGUNG